In a phase 3 trial conducted by Horn et al. it was shown that the addition of the anti PD-L1 antibody atezolizumab to chemotherapy in the first-line treatment of extensive SCLC resulted in significantly longer overall survival (OS) and progression-free survival than chemotherapy alone (2). This evidence concerns the gene CD274 and small cell lung carcinoma.